SightfileU.S. market data from official filings

Companies › PMCB

PHARMACYTE BIOTECH INC (PMCB)

Institutional ownership, SEC filings and insider activity

Sector: Healthcare & Pharma · SEC CIK 0001157075 · EDGAR filings · Updated 2026-07-17

PHARMACYTE BIOTECH INC (PMCB) has reported institutional ownership of 9.0%, with 32 institutional managers holding positions valued at $643.2K per the latest 13F reporting period. SEC filings include an active notice of delisting or failure to satisfy a continued listing rule (8-K Item 3.01), substantial-doubt (going concern) disclosure per the filings.

Institutional ownership
9.0%
Institutional managers
32
Reported 13F value
$643.2K
Insider activity
16 trans.
$128.5K net buying
Data flags
2 active
from SEC filings

Latest updates

Institutional ownership overview

According to SEC 13F filings tracked by Sightfile, PHARMACYTE BIOTECH INC has 32 institutional holders and institutional ownership of 9.0%.

Insider activity

Insiders reported 16 transactions (6 buys, 0 sells) across 5 reporting insiders, with a net reported value of $128.5K.

Data flags from SEC filings

Active notice of delisting or failure to satisfy a continued listing rule (8-K Item 3.01), most recently filed 2025-12-05 (recurring since 2022-02-17) — source filing. The authoritative details are those stated in the filing itself.
Active substantial-doubt (going concern) disclosure per the filings, most recently filed 2021-08-10 (recurring since 2020-03-13) — source filing. The authoritative details are those stated in the filing itself.

Related companies

P3 HEALTH PARTNERS INC (PIII) · Kiora Pharmaceuticals Inc (KPRX) · GT BIOPHARMA INC (GTBP) · INNOVATIVE EYEWEAR INC (LUCY) · INTERCURE LTD COM NEW (INCR) · Revelation Biosciences Inc (REVB)

See full history, cross-references and alerts on Sightfile
Sightfile provides information only — not investment advice, recommendations, or an assessment of any security. Data is derived from official public sources (SEC EDGAR and U.S. government agencies), may contain errors or delays, and should be verified against the source filing before relying on it.
Data sources: SEC EDGAR (filings, 13F, FTD), aggregated by Sightfile. Page updated 2026-07-17.